Need and value of targeted immunosuppressive therapy in giant cell arteritis | RMD Open

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest Content

Archive

For authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a correction. Please see:

Correction: Need and value of targeted immunosuppressive therapy in giant cell arteritis - March 01, 2022

Vasculitis

Review

Need and value of targeted immunosuppressive therapy in giant cell arteritis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Sandovici M, van der Geest KSM, van Sleen Y, et al

Need and value of targeted immunosuppressive therapy in giant cell arteritis

RMD Open 2022;8:e001652. doi: 10.1136/rmdopen-2021-001652